DOCUMENTED STRAINS. HEARTY KIDS. · 2018. 6. 18. · DOCUMENTED STRAINS. HEARTY KIDS. . Lallemand...

4
DOCUMENTED STRAINS. HEARTY KIDS. www.lallemand-health-solutions.com Lallemand Health Solutions provides a wide selection of targeted probiotic strains, with clinically proven and specifically designed formulations that support the natural defenses of babies and kids. 3 STRAINS SYNBIOTIC: ProBioBaby ® Lactobacillus helveticus Rosell ® -52 Bifidobacterium infantis Rosell ® -33 Bifidobacterium bifidum Rosell ® -71 + FOS

Transcript of DOCUMENTED STRAINS. HEARTY KIDS. · 2018. 6. 18. · DOCUMENTED STRAINS. HEARTY KIDS. . Lallemand...

  • DOCUMENTEDSTRAINS.HEARTY KIDS.

    www.lallemand-health-solutions.com

    Lallemand Health Solutions provides a wide selection of targeted probiotic strains, with clinically proven and specifically designed formulations that support the natural defenses of babies and kids.

    3 STRAINS SYNBIOTIC: ProBioBaby®Lactobacillus helveticus Rosell®-52Bifidobacterium infantis Rosell®-33Bifidobacterium bifidum Rosell®-71 + FOS

  • Synbiotic: ProBioBaby®

    AN INTEGRATED RESEARCH PLATEFORM

    3 STRAINS

    From in vivo and in vitro models showing synergy of the strains…

    2 Significant reductions in pro-inflammatory factors in both models of infectionSynergistic impact of multi-strain combination pathways

    In vivo modulation of Th1 and Th2 immune responses10

    • Th1 infection model: Wistar rats challengedwith enterotoxigenic Escherichia coli (intracellular pathogen)

    • Th2 challenge model: Wistar rats challengedwith Nippostrongylus brasiliensis (extracellularpathogen)

    IDENTIFICATION • Strain deposit: Collection Nationale de Cultures de

    Microorganismes, France- Lactobacillus helveticus Rosell®-52* CNCM-I1722- Bifidobacterium infantis Rosell®-33CNCM-I3424- Bifidobacterium bidifum Rosell®-71CNCM-I3426

    • Origin: dairy

    • 16S rRNA sequence confirms the species designation andthe specific identity of our strains. The complete genome ofall three strains have been sequenced and annotated

    TNF-α (pg)/ml)

    +

    +

    Control

    N. brasiliensis

    Rosell®-52

    Rosell®-71

    Rosell®-33

    ®

    *

    1401201000 20 40 60 80p

  • AN INTEGRATED RESEARCH PLATEFORM… to Clinical studies in children

    3

    4

    Spain• 220 healthy infants between 3 and

    12 months old

    • Randomized, double-blind, placebo-controlled, parallel-group, intervention study

    • 8 weeks supplementation,12 weeks monitoring

    • 1 arm per strain and 1 placebo arm

    • 135 school-aged children (3-6 years old)

    • Healthy children who had suffered from at least three episodes of Ears Nose & Throat (ENT),bronchopulmonary or gastric disorder during the previous winter

    • Placebo or ProBioBaby® once a day for 3 months

    KEY PROBIOTIC FEATURES:• Demonstrated survival in GI tract models (acidity, bile, dynamic model1, adhesion to epithelial cells) and in human

    • Robust documentation on modes of action for each strain:- Rosell®-52 stimulates the immune system by increasing the number of immune cells, activating B

    cells and by acting on the production of cytokines2,3,4

    - Rosell®-71 increases mucin expression in the small intestine5

    - All 3 strains have demonstrated pathogen inhibition properties6,7

    - Rosell®-52 surface-layer proteins, crystalline envelope of the outer bacteria cell surface, allows L. helveticus Rosell®-52 to have a strong adhesion capacity to intestinal epithelial cells and to occupy the attachment sites of pathogenic bacteria such as E. coli8

    2 safety and tolerance studies in infants

    China• 200 healthy infants between 4 and 6

    months old

    • Randomized, double-blind, placebo-controlled, parallel-group, intervention study

    • 4 weeks supplementation,14 weeks monitoring

    • 2 arms: ProBioBaby® vs placebo

    Cazzola et al. 201011: decreased incidence of infectious episodes in children during winter

    25% REDUCTION in the relative risk of infectious disease (p=0.044) with Pro ® vs placebo

    % of children with at least one adverse health event

    Placebo

    0 20 40 60 80

    -25%

    % of children with at least one lost day of school

    Placebo

    Probio ®

    0 20 40 60 80

    -40%

    40% REDUCTION in the number of children who missed at least one day of school because of an adverse health event (p=0.043) with Pro ® vs placebo

    3

  • REFERENCES

    ProBioBaby®

    1. Tompkins TA. et al. (2011) The impact of meals on a probiotic during transit through a model of the human upper gastrointestinal tract. BeneficiaMicrobes. 2(4): 295-303 / 2. Easo JG. et al. (2002) Immunostimulatory actions of Lactobacilli: Induction of antibody production and spleen cell proliferation by Lactobacillus delbrueckii subsp. bulgaricus and Lactobacillus acidophilus. Food and agricultural immunology. 14: 73-83. / 3. Wallace TD. et al. (2003) Interactions of lactic acid bacteria with human intestinal epithelial cells: Effects on cytokine production. Journal of Food Protection. 66 (3): 446-472. / 4. Easo et al (2002) Food & Agricultural Immunology 14: 73-83. / 5. Dykstra N.S et al. (2011) Pulse probiotic administration induces repeated small intestinal Muc3 expression in rats. Pediatr. Res. 69(3): 206-11 / 6. Sherman PM. et al. (2005) Probiotics reduce enterohemorrhagic Escherichia coli 0157:H7- and enteropathogenic E. coli 0127:H6- induced changes in polarized T84 epithelial cell monolayers by reducing bacterial adhesion and cytoskeletal rearrangements. Infection and Immunity. 73 (8):5183-5188 / 7. Atassi F. et al. (2006) In vitro antibacterial activity of Lactobacillus helveticus strain KS300 against diarrhoeagenic, uropathogenic and vaginosisassociated bacteria. Journal of Applied Microbiology 101 (2006) 647–654 / 8. Johnson-Henry KC. et al. (2006) Surface-layer protein extracts from Lactobacillus helveticus inhibit entero-haemorrhagic Escherichia coli O157:H7 adhesion to epithelial cells. Cellular Microbiology. 9(2): 356-367 / 9. Mac Pherson et al (2014) Multistrain Probiotic Modulation of Intestinal Epithelial Cells’ Immune Response to a Double-Stranded RNA Ligand, Poly(I·C), Applied and Environmental Microbiology p. 1692–1700 March 2014 Volume 80 Number 5 / 10. Cazzola M. et al. (2010a) Immunomodulatory impact of a symbiotic in TH1 and TH2 modelsof infection. Ther Adv respir Dir. 4(5): 259-270 / 11. Cazzola M. et al. (2010b) Efficacy of a synbiotic supplementation in the prevention of common winter diseases in children: a randomized, double-blind, placebo-controlled pilot study. Ther Adv Respir Dis. 4(5), 271-278

    FOR MORE INFORMATION, PLEASE CONTACT:

    Lallemand Health Solutions Inc 17975 Rue des Gouverneurs, Mirabel (Quebec) Canada J7 J2 J5`

    [email protected] www.lallemand-health-solutions.com

    This is business-to-business information not intended for the final consumer. It is based on our own research and development work and is, to the best of our knowledge, reliable. However, Lallemand does not assume any liability resulting from the use of its products, as conditions of use are beyond our control. The information provided should not be used as a substitute for any form of advice and in all cases, producers and marketers should check local regulatory requirements before use as different claims may be made depending on the regulations applicable in each country.

    Unavia

    - P

    RO

    202-

    2016

    03